TY  - JOUR
AU  - Morgensztern, Daniel
AU  - Cobo, Manuel
AU  - Ponce-Aix, Santiago
AU  - Postmus, Pieter E
AU  - Lewanski, Conrad R
AU  - Bennouna, Jaafar
AU  - Fischer, Jürgen R
AU  - Juan-Vidal, Oscar
AU  - Stewart, David J
AU  - Fasola, Gianpiero
AU  - Ardizzoni, Andrea
AU  - Bhore, Rafia
AU  - Wolfsteiner, Marianne
AU  - Talbot, Denis C
AU  - Jin-Ong, Teng
AU  - Govindan, Ramaswamy
PY  - 2018
DO  - 10.1002/cncr.31779
UR  - http://hdl.handle.net/10668/13148
T2  - Cancer
AB  - This randomized phase 2 trial compared the efficacy and safety of second-line nanoparticle albumin-bound paclitaxel (nab-paclitaxel) with or without the addition of CC-486 (an oral formulation of 5-azacytidine) in patients with advanced-stage,...
LA  - en
PB  - John Wiley & Sons
KW  - 5-azacytidine
KW  - CC-486 (oral 5-azacitidine)
KW  - Advanced
KW  - Nanoparticle albumin-bound paclitaxel (nab-paclitaxel)
KW  - Non-small cell lung cancer (NSCLC)
KW  - Nonsquamous
KW  - Safety
KW  - Second-line
KW  - Survival
KW  - Administration, Oral
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Albumins
KW  - Antibodies, Monoclonal
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Azacitidine
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Disease-Free Survival
KW  - Drug Administration Schedule
KW  - Female
KW  - Humans
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Paclitaxel
KW  - Treatment Outcome
TI  - ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC).
TY  - research article
VL  - 124
ER  -